NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds sellers of Endeavor Group Holdings, Inc. (NYSE: EDR) Class A common stock between January 15, 2025 and March 24, 2025, both dates inclusive (the “Class Period”), of the important March 18, 2026 lead plaintiff deadline. SO WHAT: If you sold Endeavor Class A common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency ...

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 21, 2026. SO WHAT: If you purchased Corcept common stock during the Class P ...

Stock Repurchase Program - Valley National Bancorp's Board of Directors approved a new stock repurchase program for up to 25 million shares of common stock, effective from April 27, 2026, to April 27, 2028 [1][2] - The current stock repurchase program is set to expire on April 26, 2026, unless terminated sooner [1] Repurchase Methods and Flexibility - Repurchases can be conducted through various methods, including open market purchases and Rule 10b5-1 trading plans, in compliance with SEC regulations [2] - The program does not obligate Valley to acquire a specific number of shares and can be suspended or discontinued at the company's discretion [2] Company Overview - Valley National Bank, a regional financial institution and principal subsidiary of Valley National Bancorp, has approximately $64 billion in assets and operates over 200 offices across several states [3] - The bank offers a full range of consumer, commercial, and wealth management solutions, emphasizing a relationship-led approach to support community investment and corporate citizenship [3]

Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Results Expected in First Half of 2027 Enrollment Completed in VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose Exp ...

Fourth Quarter Highlights† Reported revenue of $393.9 million, up 11%Constant currency revenue* and constant currency revenue, organic* up 10% and up 7%, respectivelyGAAP operating margin of 13.8%, compared to 10.3% in prior year periodNon-GAAP operating margin* of 21.0%, compared to 19.6% in prior year periodGAAP EPS $0.63, up 37%Non-GAAP EPS* $1.04, up 12%Free cash flow* generation of $74.0 million, up 13% Fiscal Year 2025 Highlights† Reported revenue of $1.516 billion, up 12%Constant currency revenue* an ...

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in a fireside chat as part of the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3 at 9:50 a.m. ET. To listen to a live webcast of this event, or access an archived we ...

Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year. Combined revenues of the Company's four growth products increased to $161.3 million and $521.8 million in the fourth quarter and full year 2025, representing year-over-year growth of 45% and 40% respectively. The strong growth in both periods was driven by an increase in net sales of Qelbree® and GOCOVRI®, and the addition of sales from ZURZUVAE® and ...

FY2025 Net Sales $1.49 Billion and Diluted EPS of $5.24 Per Share; Reaffirms FY2026 Guidance and Maintains Annual Cash Dividend of $3.20 for 2026 NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Interparfums, Inc. (NASDAQ GS: IPAR) (“Interparfums” or the “Company”) today reported record results for the fourth quarter and full year ended December 31, 2025. Financial Highlights:($ in millions, except per share amounts)Three Months EndedDecember 31,Year EndedDecember 31,20252024% Change20252024% Ch ...

THORNTON, Colo., Feb. 24, 2026 (GLOBE NEWSWIRE) -- MYR Group Inc. (“MYR Group”) (NASDAQ: MYRG), a holding company of leading specialty contractors serving the electric utility infrastructure, commercial and industrial construction markets in the United States and Canada, announced it will attend the Jefferies Power, Energy, Clean Energy & Utilities investor conference. MYR Group’s Chief Executive Officer, Rick Swartz; Chief Financial Officer, Kelly Huntington; and Vice President, Investor Relations and Trea ...

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the following investor conferences in March 2026. TD Cowen 46th Annual Health Care Conference Date & Time: T ...